---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-283769"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T21:02:49.106057+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte appoints Jacks Lee to Board of Directors, effective Nov 27, 2023

## Summary
- Jacks Lee appointed as Class II director, term expires at 2025 annual meeting.
- Lee appointed to Audit Committee; Board determined independent under Nasdaq rules.
- Initial grant of 30,000 stock options, vesting 1/3 at one year and monthly over 36 months.
- Annual grants: option for 15,000 shares and 2,500 RSUs, with accelerated vesting on change of control.
- Annual cash retainers: $40,000 for Board service, plus $10,000 for Audit Committee.

## SEC filing metadata
- accession: 0001193125-23-283769
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000119312523283769/0001193125-23-283769-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000119312523283769/d604212d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-283769
- JSON: https://secwatch.observer/filing/0001193125-23-283769.json
- Plain text: https://secwatch.observer/filing/0001193125-23-283769.txt

## Key facts
- Executive change
  Jacks Lee was appointed as Class II Director at Vaxcyte, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: appointed Jacks Lee to the Board as a Class II director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000119312523283769/0001193125-23-283769-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.